查看犬血管肉瘤的治疗：2000 年及以后的源代码

== 结论 (Conclusion) ==

HSA 是一种侵袭性和恶性肿瘤，受影响的狗预后严重。手术和化疗在延长犬 HSA 患者的生存时间和提高生活质量方面收效甚微。然而，护理和治疗的最新进展正在延长生存时间，并为受影响的狗提供更好的生活质量。随着新筛查方法的发展，HSA 的早期检测可能允许在明显的临床症状或严重可检测的疾病发展之前开始治疗[76] 参与转移级联反应的新分子机制的鉴定为开发旨在利用各种生物学途径的独特治疗方法打开了大门。特别是，抑制血管生成一直是众多临床研究的重点。抑制血管生成似乎是安全的，并且与化疗不同，不会引起耐药性。尽管所讨论的许多药物仍在开发和审查中，但使用结合创新治疗方式的多模式方法显然可能为受 HSA 影响的狗提供最佳治疗选择。


HSA is an aggressive and malignant neoplasia, and affected dogs have a grave prognosis. Surgery and chemotherapy have had limited success in prolonging survival times and increasing quality of life in canine HSA patients. However, recent advances in care and treatment are increasing survival times and providing a better quality of life for affected dogs. With the development of new screening methods, early detection of HSA may allow treatment to commence before the development of overt clinical signs or grossly detectable disease.76 The identification of new molecular mechanisms involved in the metastatic cascade has opened the doors for the development of unique treatments designed to utilize various biologic avenues. In particular, inhibition of angiogenesis has been the focus of numerous clinical studies. Inhibition of angiogenesis seems to be safe and, unlike chemotherapy, does not induce drug resistance. Although many of the agents discussed are still undergoing development and review, the use of a multimodality approach incorporating innovative treatment modalities apparently may offer the best therapeutic option for dogs affected with HSA.

<br>